安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Shenogen
icaritin phase IIA trial showed favorable safety profiles and preliminary durable survival benefits in advanced HCC patients in BMC Cancer online Publication
- Organization | Beijing Shenogen Biomedical Co. , Ltd
Beijing Shenogen Biomedical Co , Ltd Report issue For profit Phase 3 Founded: Beijing China (2010) Organization Overview
- Beijing Shenogen Pharma Group Ltd. - Drug pipelines, Patents, Clinical . . .
November 22, 2017 -- Lee’s Pharm and Beijing Shenogen Pharma announced a second cancer partnership that involves Shenogen’s icaritin, a small molecule, TCM-derived treatment currently in China Phase III trials for hepatocellular carcinoma In the latest joint effort, Lee’s Pharm will pair its PD-L1 candidate with icaritin
- Beijing Shenogen Biomedical Co. , Ltd:Company Profile Technical . . .
Mentioned companies in the market reports of major market categories and sectors by Beijing Shenogen Biomedical Co , Ltd
- Shenogen Pharma
Shenogen aims to develop and commercialize first-in-class therapeutics for cancer and autoimmune diseases Our first and leading compound Icaritin is an excellent example of Shen Nong meeting Gene, as Icaritin is isolated from a traditional Chinese herb, and is currently being examined as a First-in-Class drug candidate in phase III clinical
- 北京盛诺基医药科技股份有限公司（官网）
盛诺基医药公司2006年成立于北京，我们的愿景是成为立足中国且独具特色的世界级生物医药公司。 以“创新医药，成就健康”为使命，采用现代生物技术在癌症… 新闻中心 中国科技新闻网 药渡：ERK ULK1 NCOA4 铁自噬通路：淫羊藿提取物治疗肝细胞癌新机制 202503-20 中国科技新闻网 中国经济网 人民日报健康客户端：盛诺基医药淫羊藿素软胶囊新增适应症获临床批件 202501-03 中国科技新闻网 药渡：复旦大学发现淫羊藿素联合免疫佐剂与经动脉放射栓塞术TARE用于肝癌治疗的新方法
- Shenogen
Shenogen aims to develop and commercialize first-in-class therapeutics for cancer and autoimmune diseases With the mission of “Better Medicine, Better Life”, we aim is to be a leading Chinese biopharmaceutical company with growing footprint worldwide
- Shenogen - Products, Competitors, Financials, Employees, Headquarters . . .
Shenogen operates as a drug discovery and development company It focuses on the development of therapeutics for cancer treatment The company was founded in 2006 and is based in Beijing, China Shenogen has filed 1 patent
|
|
|